SEC EDGAR filings, ownership reports, and insider transactions for ASTRAZENECA PLC.
| Form type | Document | Filing | Description | Filing date | Reporting date | File number(s) |
|---|---|---|---|---|---|---|
| 6-K | Open Document | Open Filing | AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON | 08 Jan 2026 | 08 Jan 2026 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Jan 2026 | 02 Jan 2026 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 22 Dec 2025 | 22 Dec 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC | 22 Dec 2025 | 22 Dec 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB | 22 Dec 2025 | 22 Dec 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 19 Dec 2025 | 19 Dec 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | SUBCUTANEOUS SAPHNELO APPROVED IN EU | 16 Dec 2025 | 16 Dec 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC | 16 Dec 2025 | 16 Dec 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 04 Dec 2025 | 04 Dec 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 01 Dec 2025 | 01 Dec 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Dec 2025 | 01 Dec 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER | 26 Nov 2025 | 26 Nov 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND | 24 Nov 2025 | 24 Nov 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | KOSELUGO (SELUMETINIB) APPROVED IN THE US | 20 Nov 2025 | 20 Nov 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 17 Nov 2025 | 17 Nov 2025 | 001-11960 |
| 25-NSE | Open Document | Open Filing | 14 Nov 2025 | 001-11960 | ||
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 14 Nov 2025 | 14 Nov 2025 | 001-11960 |
| 144 | Open Document | Open Filing | 12 Nov 2025 | 001-11960 | ||
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 10 Nov 2025 | 10 Nov 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | 9M AND Q3 2025 RESULTS | 06 Nov 2025 | 06 Nov 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | RESULT OF GENERAL MEETING | 03 Nov 2025 | 03 Nov 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Nov 2025 | 03 Nov 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 03 Nov 2025 | 03 Nov 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR DECLARATION | 28 Oct 2025 | 28 Oct 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | KOSELUGO (SELUMETINIB) APPROVED IN THE EU | 28 Oct 2025 | 28 Oct 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TEZSPIRE APPROVED IN EU FOR CRSWNP | 22 Oct 2025 | 22 Oct 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | US FDA APPROVES TEZSPIRE IN CRSWNP | 20 Oct 2025 | 20 Oct 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO | 20 Oct 2025 | 20 Oct 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES | 14 Oct 2025 | 14 Oct 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL | 07 Oct 2025 | 07 Oct 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 | 06 Oct 2025 | 06 Oct 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Oct 2025 | 01 Oct 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 | 29 Sep 2025 | 29 Sep 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN HARMONISES LISTING STRUCTURE | 29 Sep 2025 | 29 Sep 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | 6-K | 29 Sep 2025 | 29 Sep 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 25 Sep 2025 | 25 Sep 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | KOSELUGO RECOMMENDED FOR EU APPROVAL | 22 Sep 2025 | 22 Sep 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP | 22 Sep 2025 | 22 Sep 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC | 17 Sep 2025 | 17 Sep 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON RESOLUTE PHASE III TRIAL | 17 Sep 2025 | 17 Sep 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Sep 2025 | 02 Sep 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 28 Aug 2025 | 28 Aug 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 26 Aug 2025 | 26 Aug 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 21 Aug 2025 | 21 Aug 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 18 Aug 2025 | 18 Aug 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 15 Aug 2025 | 15 Aug 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 12 Aug 2025 | 12 Aug 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Aug 2025 | 01 Aug 2025 | 001-11960 |
| 6-K | Open Document | Data | Open Filing | FORM 6-K | 29 Jul 2025 | 30 Jun 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS | 24 Jul 2025 | 24 Jul 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA PLANS TO INVEST $50BN IN THE US | 22 Jul 2025 | 22 Jul 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS | 16 Jul 2025 | 16 Jul 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL | 14 Jul 2025 | 14 Jul 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN THE EU FOR BLADDER CANCER | 07 Jul 2025 | 07 Jul 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jul 2025 | 01 Jul 2025 | 001-11960 |
| 11-K | Open Document | Open Filing | FORM 11-K | 26 Jun 2025 | 31 Dec 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER | 24 Jun 2025 | 24 Jun 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC | 13 Jun 2025 | 13 Jun 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 12 Jun 2025 | 12 Jun 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL | 06 Jun 2025 | 06 Jun 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 02 Jun 2025 | 02 Jun 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Jun 2025 | 02 Jun 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER | 27 May 2025 | 27 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 23 May 2025 | 23 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR DECLARATION | 21 May 2025 | 21 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ACQUISITION OF ESOBIOTEC COMPLETED | 20 May 2025 | 20 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER | 09 May 2025 | 09 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER | 07 May 2025 | 07 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL | 06 May 2025 | 06 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS | 02 May 2025 | 02 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 01 May 2025 | 01 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 May 2025 | 01 May 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL | 29 Apr 2025 | 29 Apr 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON CAPITELLO-280 PHASE III TRIAL | 29 Apr 2025 | 29 Apr 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | 1ST QUARTER RESULTS | 29 Apr 2025 | 29 Apr 2025 | 001-11960 |
| SCHEDULE 13G/A | Open Document | Open Filing | 23 Apr 2025 | 005-55247 | ||
| 6-K | Open Document | Open Filing | ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC | 22 Apr 2025 | 22 Apr 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | RESULT OF AGM | 11 Apr 2025 | 11 Apr 2025 | 001-11960 |
| SCHEDULE 13G/A | Open Document | Open Filing | 10 Apr 2025 | |||
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN EU FOR AEGEAN | 04 Apr 2025 | 04 Apr 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER | 04 Apr 2025 | 04 Apr 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Apr 2025 | 01 Apr 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL | 31 Mar 2025 | 31 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN THE US FOR BLADDER CANCER | 31 Mar 2025 | 31 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING | 21 Mar 2025 | 21 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT | 17 Mar 2025 | 17 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC | 17 Mar 2025 | 17 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO ACQUIRE ESOBIOTEC | 17 Mar 2025 | 17 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 12 Mar 2025 | 12 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 07 Mar 2025 | 07 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | NOTICE OF AGM | 07 Mar 2025 | 07 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER | 07 Mar 2025 | 07 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 07 Mar 2025 | 07 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2025 | 06 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 05 Mar 2025 | 05 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Mar 2025 | 03 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN | 03 Mar 2025 | 03 Mar 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER | 28 Feb 2025 | 28 Feb 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER | 26 Feb 2025 | 26 Feb 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | FILING OF FORM 20-F WITH SEC | 19 Feb 2025 | 19 Feb 2025 | 001-11960 |
| IRANNOTICE | Open Document | Open Filing | IRANNOTICE | 18 Feb 2025 | 001-11960 | |
| 20-F | Open Document | Data | Open Filing | FORM 20-F | 18 Feb 2025 | 31 Dec 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 18 Feb 2025 | 18 Feb 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 18 Feb 2025 | 18 Feb 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ANNUAL FINANCIAL REPORT | 18 Feb 2025 | 18 Feb 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTORATE CHANGE | 18 Feb 2025 | 18 Feb 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | FINAL RESULTS | 06 Feb 2025 | 06 Feb 2025 | 001-11960 |
| EFFECT | Open Document | Open Filing | 05 Feb 2025 | 333-284374 | ||
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Feb 2025 | 03 Feb 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC | 03 Feb 2025 | 03 Feb 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN US FOR BREAST CANCER POST ET | 28 Jan 2025 | 28 Jan 2025 | 001-11960 |
| SCHEDULE 13D/A | Open Document | Open Filing | 24 Jan 2025 | |||
| F-6 | Open Document | Open Filing | 21 Jan 2025 | 333-284374 | ||
| 6-K | Open Document | Open Filing | DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER | 21 Jan 2025 | 21 Jan 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL | 17 Jan 2025 | 17 Jan 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Jan 2025 | 02 Jan 2025 | 001-11960 |
| 6-K | Open Document | Open Filing | DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU | 26 Dec 2024 | 26 Dec 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL | 23 Dec 2024 | 23 Dec 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTORATE CHANGE | 16 Dec 2024 | 16 Dec 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC | 05 Dec 2024 | 05 Dec 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL | 04 Dec 2024 | 04 Dec 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 02 Dec 2024 | 02 Dec 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Dec 2024 | 02 Dec 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER | 25 Nov 2024 | 25 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 20 Nov 2024 | 20 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA | 18 Nov 2024 | 18 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 15 Nov 2024 | 15 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 15 Nov 2024 | 15 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 13 Nov 2024 | 13 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA INVESTS $3.5 BILLION IN US | 12 Nov 2024 | 12 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | KOMET PHASE III TRIAL MET PRIMARY ENDPOINT | 12 Nov 2024 | 12 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | 9M AND Q3 2024 RESULTS | 12 Nov 2024 | 12 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN | 12 Nov 2024 | 12 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS | 08 Nov 2024 | 08 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Nov 2024 | 01 Nov 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN CHINA PRESIDENT UNDER INVESTIGATION | 30 Oct 2024 | 30 Oct 2024 | 001-11960 |
| SC 13G | Open Document | Open Filing | SC 13G | 28 Oct 2024 | ||
| 6-K | Open Document | Open Filing | FORM 6-K | 21 Oct 2024 | 21 Oct 2024 | 001-11960 |
| SC 13G | Open Document | Open Filing | SC 13G | 11 Oct 2024 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET | 07 Oct 2024 | 07 Oct 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Oct 2024 | 01 Oct 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER | 26 Sep 2024 | 26 Sep 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA | 23 Sep 2024 | 23 Sep 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 | 23 Sep 2024 | 23 Sep 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US | 20 Sep 2024 | 20 Sep 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FASENRA EGPA US FDA APPROVAL | 18 Sep 2024 | 18 Sep 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 13 Sep 2024 | 13 Sep 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Sep 2024 | 02 Sep 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER | 16 Aug 2024 | 16 Aug 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Aug 2024 | 01 Aug 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING | 30 Jul 2024 | 30 Jul 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS | 29 Jul 2024 | 29 Jul 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER | 26 Jul 2024 | 26 Jul 2024 | 001-11960 |
| 6-K | Open Document | Data | Open Filing | FORM 6K | 25 Jul 2024 | 30 Jun 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ACQUISITION OF AMOLYT PHARMA COMPLETED | 15 Jul 2024 | 15 Jul 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jul 2024 | 01 Jul 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL | 01 Jul 2024 | 01 Jul 2024 | 001-11960 |
| 11-K | Open Document | Open Filing | ANNUAL REPORT | 26 Jun 2024 | 31 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL | 25 Jun 2024 | 25 Jun 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER | 25 Jun 2024 | 25 Jun 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON CAPITELLO-290 PHASE III TRIAL | 18 Jun 2024 | 18 Jun 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER | 17 Jun 2024 | 17 Jun 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 12 Jun 2024 | 12 Jun 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 04 Jun 2024 | 04 Jun 2024 | 001-11960 |
| 25-NSE | Open Document | Open Filing | 04 Jun 2024 | 001-11960 | ||
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 03 Jun 2024 | 03 Jun 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Jun 2024 | 03 Jun 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU | 03 Jun 2024 | 03 Jun 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER | 28 May 2024 | 28 May 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 | 21 May 2024 | 21 May 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE | 20 May 2024 | 20 May 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT | 16 May 2024 | 16 May 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 15 May 2024 | 15 May 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT | 07 May 2024 | 07 May 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL | 02 May 2024 | 02 May 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 May 2024 | 01 May 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL | 29 Apr 2024 | 29 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW | 29 Apr 2024 | 29 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | 1ST QUARTER RESULTS | 25 Apr 2024 | 25 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | RESULT OF AGM | 11 Apr 2024 | 11 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% | 11 Apr 2024 | 11 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS | 08 Apr 2024 | 08 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC | 05 Apr 2024 | 05 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Apr 2024 | 02 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | VOYDEYA APPROVED IN US | 02 Apr 2024 | 02 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER | 02 Apr 2024 | 02 Apr 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ULTOMIRIS APPROVED IN THE US FOR NMOSD | 25 Mar 2024 | 25 Mar 2024 | 001-11960 |
| DFAN14A | Open Document | Open Filing | DFAN14A | 19 Mar 2024 | ||
| F-3ASR | Open Document | Open Filing | F-3ASR | 19 Mar 2024 | 333-278067 | |
| 6-K | Open Document | Open Filing | FORM 6-K | 19 Mar 2024 | 19 Mar 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO ACQUIRE AMOLYT | 14 Mar 2024 | 14 Mar 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 12 Mar 2024 | 12 Mar 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 07 Mar 2024 | 07 Mar 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | NOTICE OF AGM | 07 Mar 2024 | 07 Mar 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2024 | 06 Mar 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2024 | 06 Mar 2024 | 001-11960 |
| CERT | Open Document | Open Filing | 06 Mar 2024 | 001-11960 | ||
| 8-A12B | Open Document | Open Filing | 8-A12B | 05 Mar 2024 | 001-11960 | |
| 6-K | Open Document | Open Filing | EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC | 04 Mar 2024 | 04 Mar 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Mar 2024 | 01 Mar 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 26 Feb 2024 | 26 Feb 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | VOYDEYA RECOMMENDED FOR EU APPROVAL | 26 Feb 2024 | 26 Feb 2024 | 001-11960 |
| 424B2 | Open Document | Open Filing | 424B2 | 23 Feb 2024 | 333-256406 | |
| 6-K | Open Document | Open Filing | ASTRAZENECA PRICES A $5BN BOND OFFERING | 22 Feb 2024 | 22 Feb 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 22 Feb 2024 | 22 Feb 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 22 Feb 2024 | 22 Feb 2024 | 001-11960 |
| FWP | Open Document | Open Filing | FWP | 22 Feb 2024 | 333-256406 | |
| SC TO-T/A | Open Document | Open Filing | SC TO-T/A | 21 Feb 2024 | ||
| 424B2 | Open Document | Open Filing | 424B2 | 21 Feb 2024 | 333-256406 | |
| 6-K | Open Document | Open Filing | FILING OF FORM 20-F WITH SEC | 21 Feb 2024 | 21 Feb 2024 | 001-11960 |
| S-8 | Open Document | Open Filing | FORM S-8 | 20 Feb 2024 | 333-277197 | |
| IRANNOTICE | Open Document | Open Filing | IRANNOTICE | 20 Feb 2024 | 001-11960 | |
| 20-F | Open Document | Data | Open Filing | FORM 20-F | 20 Feb 2024 | 31 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ANNUAL FINANCIAL REPORT | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| SC TO-T/A | Open Document | Open Filing | SC TO-T/A | 20 Feb 2024 | ||
| 6-K | Open Document | Open Filing | FORM 6-K | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER | 20 Feb 2024 | 19 Feb 2024 | 001-11960 |
| SC TO-T/A | Open Document | Open Filing | SC TO-T/A | 15 Feb 2024 | ||
| SC 13G/A | Open Document | Open Filing | SC 13G/A | 12 Feb 2024 | ||
| 6-K | Open Document | Open Filing | FINAL RESULTS | 08 Feb 2024 | 08 Feb 2024 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Feb 2024 | 01 Feb 2024 | 001-11960 |
| SC 13G/A | Open Document | Open Filing | 24 Jan 2024 | 005-55247 | ||
| SC TO-T/A | Open Document | Open Filing | SC TO-T/A | 19 Jan 2024 | ||
| 6-K | Open Document | Open Filing | FORM 6-K | 19 Jan 2024 | 19 Jan 2024 | 001-11960 |
| SC TO-T/A | Open Document | Open Filing | SC TO-T/A | 11 Jan 2024 | ||
| CORRESP | Open Document | Open Filing | 10 Jan 2024 | |||
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Jan 2024 | 02 Jan 2024 | 001-11960 |
| SC TO-T | Open Document | Open Filing | SC TO-T | 27 Dec 2023 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA ACQUIRES GRACELL | 27 Dec 2023 | 27 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 26 Dec 2023 | 26 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL | 22 Dec 2023 | 22 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 14 Dec 2023 | 14 Dec 2023 | 001-11960 |
| SC TO-C | Open Document | Open Filing | SC TO-C | 12 Dec 2023 | ||
| 6-K | Open Document | Open Filing | FORM 6-K | 12 Dec 2023 | 12 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO ACQUIRE ICOSAVAX | 12 Dec 2023 | 12 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 01 Dec 2023 | 01 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Dec 2023 | 01 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS | 01 Dec 2023 | 01 Dec 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 24 Nov 2023 | 24 Nov 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TRUQAP APPROVED IN US FOR HR+ BREAST CANCER | 17 Nov 2023 | 17 Nov 2023 | 001-11960 |
| SC 13D/A | Open Document | Open Filing | SC 13D/A | 16 Nov 2023 | ||
| 25-NSE | Open Document | Open Filing | 14 Nov 2023 | 001-11960 | ||
| 6-K | Open Document | Open Filing | UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI | 14 Nov 2023 | 14 Nov 2023 | 001-11960 |
| 144 | Open Document | Open Filing | 13 Nov 2023 | 001-11960 | ||
| SC 13D | Open Document | Open Filing | SC 13D | 09 Nov 2023 | ||
| 6-K | Open Document | Open Filing | DIRECTOR DECLARATION | 09 Nov 2023 | 09 Nov 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER | 09 Nov 2023 | 09 Nov 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA | 09 Nov 2023 | 09 Nov 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | 9M AND Q3 2023 RESULTS | 09 Nov 2023 | 02 Nov 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Nov 2023 | 01 Nov 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS | 01 Nov 2023 | 01 Nov 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS | 03 Oct 2023 | 03 Oct 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Oct 2023 | 02 Oct 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DATO-DXD IMPROVED PFS IN BREAST CANCER | 25 Sep 2023 | 22 Sep 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT | 20 Sep 2023 | 20 Sep 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC | 15 Sep 2023 | 15 Sep 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT | 11 Sep 2023 | 11 Sep 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD | 06 Sep 2023 | 06 Sep 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Sep 2023 | 01 Sep 2023 | 001-11960 |
| 25-NSE | Open Document | Open Filing | 16 Aug 2023 | 001-11960 | ||
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Aug 2023 | 01 Aug 2023 | 001-11960 |
| 6-K | Open Document | Data | Open Filing | FORM 6K | 28 Jul 2023 | 30 Jun 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER | 28 Jul 2023 | 28 Jul 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION | 17 Jul 2023 | 17 Jul 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Jul 2023 | 03 Jul 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER | 03 Jul 2023 | 03 Jul 2023 | 001-11960 |
| 11-K | Open Document | Open Filing | ANNUAL REPORT | 28 Jun 2023 | 31 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION | 09 Jun 2023 | 09 Jun 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS | 09 Jun 2023 | 09 Jun 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS | 02 Jun 2023 | 02 Jun 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 01 Jun 2023 | 01 Jun 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jun 2023 | 01 Jun 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER | 01 Jun 2023 | 01 Jun 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER | 26 May 2023 | 26 May 2023 | 001-11960 |
| 25-NSE | Open Document | Open Filing | 25 May 2023 | 001-11960 | ||
| 6-K | Open Document | Open Filing | DIRECTORATE CHANGE | 22 May 2023 | 22 May 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER | 17 May 2023 | 17 May 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 09 May 2023 | 09 May 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA EXTENDED IN THE US FOR HEART FAILURE | 09 May 2023 | 09 May 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 May 2023 | 02 May 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER | 02 May 2023 | 02 May 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 02 May 2023 | 02 May 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | 1ST QUARTER RESULTS | 27 Apr 2023 | 27 Apr 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | RESULT OF AGM | 27 Apr 2023 | 27 Apr 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 27 Apr 2023 | 27 Apr 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | BOARD COMMITTEE CHANGES | 27 Apr 2023 | 27 Apr 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR DECLARATION | 26 Apr 2023 | 26 Apr 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI | 11 Apr 2023 | 11 Apr 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER | 05 Apr 2023 | 05 Apr 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Apr 2023 | 03 Apr 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL | 03 Apr 2023 | 03 Apr 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 | 30 Mar 2023 | 30 Mar 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 27 Mar 2023 | 27 Mar 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 22 Mar 2023 | 22 Mar 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | NOTICE OF AGM | 22 Mar 2023 | 22 Mar 2023 | 001-11960 |
| CERT | Open Document | Open Filing | 15 Mar 2023 | 001-11960 | ||
| 8-A12B | Open Document | Open Filing | 8-A12B | 13 Mar 2023 | 001-11960 | |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER | 09 Mar 2023 | 09 Mar 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 08 Mar 2023 | 08 Mar 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 08 Mar 2023 | 08 Mar 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS | 06 Mar 2023 | 06 Mar 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 03 Mar 2023 | 03 Mar 2023 | 001-11960 |
| 424B2 | Open Document | Open Filing | 424B2 | 02 Mar 2023 | 333-256406 | |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Mar 2023 | 01 Mar 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA PRICES A $2.25BN BOND OFFERING | 01 Mar 2023 | 01 Mar 2023 | 001-11960 |
| FWP | Open Document | Open Filing | FWP | 01 Mar 2023 | 333-256406 | |
| 424B2 | Open Document | Open Filing | 424B2 | 28 Feb 2023 | 333-256406 | |
| 6-K | Open Document | Open Filing | ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING | 24 Feb 2023 | 24 Feb 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET | 24 Feb 2023 | 24 Feb 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 24 Feb 2023 | 24 Feb 2023 | 001-11960 |
| SC TO-T/A | Open Document | Open Filing | SC TO-T/A | 24 Feb 2023 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901 | 23 Feb 2023 | 23 Feb 2023 | 001-11960 |
| SC TO-T/A | Open Document | Open Filing | SC TO-T | 23 Feb 2023 | ||
| 6-K | Open Document | Open Filing | FILING OF FORM 20-F WITH SEC | 22 Feb 2023 | 22 Feb 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 21 Feb 2023 | 21 Feb 2023 | 001-11960 |
| IRANNOTICE | Open Document | Open Filing | IRANNOTICE | 21 Feb 2023 | 001-11960 | |
| 20-F | Open Document | Data | Open Filing | FORM 20-F | 21 Feb 2023 | 31 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ANNUAL FINANCIAL REPORT | 21 Feb 2023 | 21 Feb 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 13 Feb 2023 | 13 Feb 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 13 Feb 2023 | 13 Feb 2023 | 001-11960 |
| SC 13G/A | Open Document | Open Filing | SC 13G/A | 10 Feb 2023 | ||
| SC 13G/A | Open Document | Open Filing | SC 13G/A | 10 Feb 2023 | ||
| 6-K | Open Document | Open Filing | FINAL RESULTS | 09 Feb 2023 | 09 Feb 2023 | 001-11960 |
| SC TO-T/A | Open Document | Open Filing | SC TO-T/A | 03 Feb 2023 | ||
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Feb 2023 | 01 Feb 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON EVUSHELD US EUA | 26 Jan 2023 | 26 Jan 2023 | 001-11960 |
| SC 13G/A | Open Document | Open Filing | 24 Jan 2023 | 005-55247 | ||
| SC TO-T | Open Document | Open Filing | SC TO-T | 23 Jan 2023 | ||
| 6-K | Open Document | Open Filing | ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED | 17 Jan 2023 | 17 Jan 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA | 11 Jan 2023 | 11 Jan 2023 | 001-11960 |
| SC TO-C | Open Document | Open Filing | SC TO-C | 09 Jan 2023 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET | 09 Jan 2023 | 09 Jan 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Jan 2023 | 03 Jan 2023 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 30 Dec 2022 | 30 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL | 28 Dec 2022 | 28 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS | 28 Dec 2022 | 28 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER | 21 Dec 2022 | 21 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN EU FOR PROSTATE CANCER | 21 Dec 2022 | 21 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA | 15 Dec 2022 | 15 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER | 08 Dec 2022 | 08 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Dec 2022 | 01 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 01 Dec 2022 | 01 Dec 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE | 30 Nov 2022 | 30 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS | 29 Nov 2022 | 29 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 23 Nov 2022 | 23 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC | 14 Nov 2022 | 14 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC | 14 Nov 2022 | 14 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC | 14 Nov 2022 | 14 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER | 14 Nov 2022 | 11 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | YTD AND Q3 2022 RESULTS | 10 Nov 2022 | 10 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA | 09 Nov 2022 | 09 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | BEYFORTUS (NIRSEVIMAB) APPROVED IN EU | 04 Nov 2022 | 04 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Nov 2022 | 01 Nov 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS | 26 Oct 2022 | 26 Oct 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON MESSINA PHASE III TRIAL | 25 Oct 2022 | 25 Oct 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER | 24 Oct 2022 | 24 Oct 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Oct 2022 | 03 Oct 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | BOARD COMMITTEE CHANGES | 30 Sep 2022 | 30 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | KOSELUGO APPROVED IN JAPAN FOR NF1 | 27 Sep 2022 | 27 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA | 27 Sep 2022 | 27 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ULTOMIRIS APPROVED IN EU FOR GMG | 23 Sep 2022 | 23 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER | 22 Sep 2022 | 22 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA | 21 Sep 2022 | 21 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT | 20 Sep 2022 | 20 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT | 16 Sep 2022 | 16 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP | 16 Sep 2022 | 16 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | EVUSHELD POSITIVE CHMP OPINION IN EU | 16 Sep 2022 | 16 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA APPROVED IN CHINA FOR CKD | 06 Sep 2022 | 06 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER | 06 Sep 2022 | 06 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Sep 2022 | 01 Sep 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | EVUSHELD APPROVED FOR COVID-19 IN JAPAN | 30 Aug 2022 | 30 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF | 30 Aug 2022 | 30 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE | 30 Aug 2022 | 30 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ULTOMIRIS APPROVED IN JAPAN FOR GMG | 25 Aug 2022 | 25 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER | 25 Aug 2022 | 25 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER | 25 Aug 2022 | 25 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL | 16 Aug 2022 | 16 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 | 15 Aug 2022 | 15 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC | 12 Aug 2022 | 12 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ACQUISITION OF TENEOTWO COMPLETED | 11 Aug 2022 | 11 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN THE US FOR HER2-LOW MBC | 08 Aug 2022 | 08 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER | 04 Aug 2022 | 04 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 01 Aug 2022 | 01 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Aug 2022 | 01 Aug 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 01 Aug 2022 | 01 Aug 2022 | 001-11960 |
| 6-K | Open Document | Data | Open Filing | FORM 6-K | 29 Jul 2022 | 30 Jun 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | CHAIR SUCCESSION | 29 Jul 2022 | 29 Jul 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA | 25 Jul 2022 | 25 Jul 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG | 25 Jul 2022 | 25 Jul 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC | 25 Jul 2022 | 25 Jul 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC | 19 Jul 2022 | 19 Jul 2022 | 001-11960 |
| SC 13G | Open Document | Open Filing | 08 Jul 2022 | 005-55247 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER | 05 Jul 2022 | 05 Jul 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jul 2022 | 01 Jul 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER | 30 Jun 2022 | 30 Jun 2022 | 001-11960 |
| 11-K | Open Document | Open Filing | ANNUAL REPORT | 29 Jun 2022 | 31 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL | 27 Jun 2022 | 27 Jun 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER | 27 Jun 2022 | 27 Jun 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS | 21 Jun 2022 | 21 Jun 2022 | 001-11960 |
| 25-NSE | Open Document | Open Filing | 10 Jun 2022 | 001-11960 | ||
| 25-NSE | Open Document | Open Filing | 09 Jun 2022 | 001-11960 | ||
| 6-K | Open Document | Open Filing | ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER | 06 Jun 2022 | 06 Jun 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 01 Jun 2022 | 01 Jun 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jun 2022 | 01 Jun 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 20 May 2022 | 20 May 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | APPOINTMENT OF JOINT CORPORATE BROKERS | 09 May 2022 | 09 May 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 06 May 2022 | 06 May 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER | 05 May 2022 | 05 May 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT | 05 May 2022 | 05 May 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT | 05 May 2022 | 05 May 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC | 04 May 2022 | 04 May 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 May 2022 | 03 May 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | RESULT OF AGM | 29 Apr 2022 | 29 Apr 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS | 29 Apr 2022 | 29 Apr 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | FIRST QUARTER 2022 RESULTS | 29 Apr 2022 | 29 Apr 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG | 28 Apr 2022 | 28 Apr 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER | 27 Apr 2022 | 27 Apr 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO | 25 Apr 2022 | 25 Apr 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC | 19 Apr 2022 | 19 Apr 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Apr 2022 | 01 Apr 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL | 29 Mar 2022 | 29 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | EVUSHELD APPROVED IN THE EU FOR COVID-19 | 28 Mar 2022 | 28 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 25 Mar 2022 | 25 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | EVUSHELD POSITIVE EU CHMP OPINION | 24 Mar 2022 | 24 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA | 24 Mar 2022 | 24 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | NOTICE OF AGM | 23 Mar 2022 | 23 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 23 Mar 2022 | 23 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS | 17 Mar 2022 | 17 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER | 14 Mar 2022 | 14 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS | 14 Mar 2022 | 14 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 09 Mar 2022 | 09 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 07 Mar 2022 | 07 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 01 Mar 2022 | 01 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Mar 2022 | 01 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 | 01 Mar 2022 | 01 Mar 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | FILING OF FORM 20-F WITH SEC | 23 Feb 2022 | 23 Feb 2022 | 001-11960 |
| IRANNOTICE | Open Document | Open Filing | IRANNOTICE | 22 Feb 2022 | 001-11960 | |
| 20-F | Open Document | Data | Open Filing | FORM 20F | 22 Feb 2022 | 31 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT | 22 Feb 2022 | 22 Feb 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC | 22 Feb 2022 | 22 Feb 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | SAPHNELO APPROVED IN EU FOR SLE | 16 Feb 2022 | 16 Feb 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE | 15 Feb 2022 | 15 Feb 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 11 Feb 2022 | 11 Feb 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN: FULL YEAR AND Q4 2021 RESULTS | 10 Feb 2022 | 10 Feb 2022 | 001-11960 |
| SC 13G/A | Open Document | Open Filing | 07 Feb 2022 | 005-55247 | ||
| SC 13G/A | Open Document | Open Filing | SEC SCHEDULE 13G | 04 Feb 2022 | 005-55247 | |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Feb 2022 | 01 Feb 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER | 19 Jan 2022 | 19 Jan 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC | 19 Jan 2022 | 19 Jan 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER | 18 Jan 2022 | 18 Jan 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 | 07 Jan 2022 | 07 Jan 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED | 05 Jan 2022 | 05 Jan 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 04 Jan 2022 | 04 Jan 2022 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL | 29 Dec 2021 | 29 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG | 21 Dec 2021 | 21 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA | 20 Dec 2021 | 20 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE | 20 Dec 2021 | 20 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 15 Dec 2021 | 15 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | EVUSHELD US FDA EUA | 09 Dec 2021 | 09 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN | 07 Dec 2021 | 07 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 01 Dec 2021 | 01 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Dec 2021 | 01 Dec 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA | 30 Nov 2021 | 30 Nov 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 15 Nov 2021 | 15 Nov 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN: YEAR TO DATE AND Q3 2021 RESULTS | 12 Nov 2021 | 12 Nov 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Nov 2021 | 01 Nov 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR | 01 Nov 2021 | 01 Nov 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER | 25 Oct 2021 | 25 Oct 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER | 18 Oct 2021 | 18 Oct 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER | 15 Oct 2021 | 15 Oct 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS | 12 Oct 2021 | 12 Oct 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU GRANTED BTD FOR BREAST CANCER | 04 Oct 2021 | 04 Oct 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Oct 2021 | 01 Oct 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 30 Sep 2021 | 30 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES | 29 Sep 2021 | 29 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | SAPHNELO APPROVED IN JAPAN FOR SLE | 28 Sep 2021 | 28 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT | 24 Sep 2021 | 24 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | BOARD COMMITTEE CHANGE | 23 Sep 2021 | 23 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | NEW SUSTAINABILITY COMMITTEE OF THE BOARD | 23 Sep 2021 | 23 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT | 21 Sep 2021 | 21 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72% | 20 Sep 2021 | 20 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDON | 09 Sep 2021 | 09 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFIC | 09 Sep 2021 | 09 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH | 03 Sep 2021 | 03 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Sep 2021 | 01 Sep 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA APPROVED IN JAPAN FOR CKD | 26 Aug 2021 | 26 Aug 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT | 26 Aug 2021 | 26 Aug 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON ULTOMIRIS PHASE III ALS TRIAL | 20 Aug 2021 | 20 Aug 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINT | 20 Aug 2021 | 20 Aug 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 16 Aug 2021 | 16 Aug 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON US REVIEW OF ROXADUSTAT | 11 Aug 2021 | 11 Aug 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA APPROVED IN THE EU FOR CKD | 09 Aug 2021 | 09 Aug 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINT | 09 Aug 2021 | 09 Aug 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Aug 2021 | 02 Aug 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | SAPHNELO APPROVED IN THE US FOR SLE | 02 Aug 2021 | 02 Aug 2021 | 001-11960 |
| 6-K/A | Open Document | Data | Open Filing | FORM 6-K/A | 30 Jul 2021 | 30 Jun 2021 | 001-11960 |
| 6-K | Open Document | Data | Open Filing | FORM 6-K | 30 Jul 2021 | 30 Jun 2021 | 001-11960 |
| SC 13G | Open Document | Open Filing | SC 13G | 27 Jul 2021 | ||
| 6-K | Open Document | Open Filing | ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNH | 26 Jul 2021 | 26 Jul 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTORATE CHANGE | 22 Jul 2021 | 22 Jul 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 21 Jul 2021 | 21 Jul 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 21 Jul 2021 | 21 Jul 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 21 Jul 2021 | 21 Jul 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ACQUISITION OF ALEXION COMPLETED | 21 Jul 2021 | 21 Jul 2021 | 001-11960 |
| F-6EF | Open Document | Open Filing | REGISTRATION OF AMERICAN DEPOSITAR RECEIPT SHARES | 19 Jul 2021 | 333-258002 | |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC | 19 Jul 2021 | 19 Jul 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT | 16 Jul 2021 | 16 Jul 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 14 Jul 2021 | ||
| 425 | Open Document | Open Filing | 425 | 14 Jul 2021 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK | 14 Jul 2021 | 14 Jul 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA | 08 Jul 2021 | 08 Jul 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 06 Jul 2021 | ||
| 425 | Open Document | Open Filing | 425 | 06 Jul 2021 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU | 06 Jul 2021 | 06 Jul 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jul 2021 | 01 Jul 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 30 Jun 2021 | ||
| 11-K | Open Document | Open Filing | FORM 11-K | 29 Jun 2021 | 31 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD | 28 Jun 2021 | 28 Jun 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE | 28 Jun 2021 | 28 Jun 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER | 24 Jun 2021 | 24 Jun 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ORPATHYS APPROVED IN CHINA FOR LUNG CANCER | 23 Jun 2021 | 23 Jun 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1 | 22 Jun 2021 | 22 Jun 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON AZD7442 STORM CHASER TRIAL | 15 Jun 2021 | 15 Jun 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB | 07 Jun 2021 | 07 Jun 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 04 Jun 2021 | ||
| 425 | Open Document | Open Filing | 425 | 04 Jun 2021 | ||
| 6-K | Open Document | Open Filing | LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER | 04 Jun 2021 | 04 Jun 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICER | 04 Jun 2021 | 04 Jun 2021 | 001-11960 |
| CERT | Open Document | Open Filing | 03 Jun 2021 | 001-11960 | ||
| 6-K | Open Document | Open Filing | PUBLICATION OF FINAL TERMS | 02 Jun 2021 | 02 Jun 2021 | 001-11960 |
| 8-A12B | Open Document | Open Filing | 8-A12B | 01 Jun 2021 | 001-11960 | |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 01 Jun 2021 | 01 Jun 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jun 2021 | 01 Jun 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 28 May 2021 | 28 May 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG | 28 May 2021 | 28 May 2021 | 001-11960 |
| 424B2 | Open Document | Open Filing | 424B2 | 27 May 2021 | 333-256406 | |
| 425 | Open Document | Open Filing | 425 | 27 May 2021 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA PRICES A EUR800M BOND OFFERING | 27 May 2021 | 27 May 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA PRICES A $7BN BOND OFFERING | 26 May 2021 | 26 May 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 26 May 2021 | 26 May 2021 | 001-11960 |
| FWP | Open Document | Open Filing | FWP | 26 May 2021 | 333-256406 | |
| FWP | Open Document | Open Filing | FWP | 26 May 2021 | 333-256406 | |
| 6-K | Open Document | Open Filing | EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUS | 25 May 2021 | 25 May 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 24 May 2021 | ||
| 424B2 | Open Document | Open Filing | 424B2 | 24 May 2021 | 333-256406 | |
| F-3ASR | Open Document | Open Filing | F-3ASR | 24 May 2021 | 333-256406 | |
| 6-K | Open Document | Open Filing | FORM 6-K | 24 May 2021 | 24 May 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN | 21 May 2021 | 21 May 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 18 May 2021 | 18 May 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | RESULT OF AGM | 11 May 2021 | 11 May 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITION | 11 May 2021 | 11 May 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 07 May 2021 | ||
| 6-K | Open Document | Open Filing | IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON | 07 May 2021 | 07 May 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 06 May 2021 | ||
| 425 | Open Document | Open Filing | 425 | 05 May 2021 | ||
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 04 May 2021 | 04 May 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA APPROVED IN THE US FOR CKD | 04 May 2021 | 04 May 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 30 Apr 2021 | ||
| 425 | Open Document | Open Filing | 425 | 30 Apr 2021 | ||
| 425 | Open Document | Open Filing | 425 | 30 Apr 2021 | ||
| 6-K | Open Document | Open Filing | AZN: FIRST QUARTER 2021 RESULTS | 30 Apr 2021 | 30 Apr 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 29 Apr 2021 | ||
| 6-K | Open Document | Open Filing | NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT | 26 Apr 2021 | 26 Apr 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION | 26 Apr 2021 | 26 Apr 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1 | 26 Apr 2021 | 26 Apr 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 16 Apr 2021 | ||
| 425 | Open Document | Open Filing | 425 | 16 Apr 2021 | ||
| 6-K | Open Document | Open Filing | US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION | 16 Apr 2021 | 16 Apr 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER | 14 Apr 2021 | 14 Apr 2021 | 001-11960 |
| 424B3 | Open Document | Open Filing | 424B3 | 13 Apr 2021 | 333-253315 | |
| EFFECT | Open Document | Open Filing | 12 Apr 2021 | 333-253315 | ||
| 425 | Open Document | Open Filing | 425 | 12 Apr 2021 | ||
| 6-K | Open Document | Open Filing | FORM 6-K | 12 Apr 2021 | 12 Apr 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | CIRCULAR AND NOTICE OF GENERAL MEETING | 12 Apr 2021 | 12 Apr 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 12 Apr 2021 | ||
| 6-K | Open Document | Open Filing | UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL | 12 Apr 2021 | 12 Apr 2021 | 001-11960 |
| F-4/A | Open Document | Open Filing | F-4/A | 09 Apr 2021 | 333-253315 | |
| CORRESP | Open Document | Open Filing | 08 Apr 2021 | |||
| SC 13G | Open Document | Open Filing | SC 13G | 08 Apr 2021 | ||
| 425 | Open Document | Open Filing | 425 | 01 Apr 2021 | ||
| 425 | Open Document | Open Filing | 425 | 01 Apr 2021 | ||
| 425 | Open Document | Open Filing | 425 | 01 Apr 2021 | ||
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Apr 2021 | 01 Apr 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | NOTICE OF AGM | 30 Mar 2021 | 30 Mar 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FORM 6-K | 30 Mar 2021 | 30 Mar 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 25 Mar 2021 | 25 Mar 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY | 25 Mar 2021 | 25 Mar 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT | 22 Mar 2021 | 22 Mar 2021 | 001-11960 |
| 4 | Open Document | Open Filing | 4 | 16 Mar 2021 | 15 Mar 2021 | 001-39067 |
| 6-K | Open Document | Open Filing | DIVESTMENT OF VIELA SHAREHOLDING COMPLETED | 16 Mar 2021 | 16 Mar 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES | 16 Mar 2021 | 16 Mar 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 12 Mar 2021 | ||
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 09 Mar 2021 | 09 Mar 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES | 04 Mar 2021 | 04 Mar 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | US COURT DECISION FAVOURS SYMBICORT PATENTS | 03 Mar 2021 | 03 Mar 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE | 02 Mar 2021 | 02 Mar 2021 | 001-11960 |
| UPLOAD | Open Document | Open Filing | 01 Mar 2021 | |||
| 6-K | Open Document | Open Filing | TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL | 01 Mar 2021 | 01 Mar 2021 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 26 Feb 2021 | ||
| 425 | Open Document | Open Filing | 425 | 25 Feb 2021 | ||
| 6-K | Open Document | Open Filing | VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US | 22 Feb 2021 | 22 Feb 2021 | 001-11960 |
| F-4 | Open Document | Open Filing | F-4 | 19 Feb 2021 | 333-253315 | |
| 6-K | Open Document | Open Filing | LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA | 17 Feb 2021 | 17 Feb 2021 | 001-11960 |
| IRANNOTICE | Open Document | Open Filing | IRANNOTICE | 16 Feb 2021 | 001-11960 | |
| 6-K | Open Document | Open Filing | FILING OF FORM 20-F WITH SEC | 16 Feb 2021 | 16 Feb 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 16 Feb 2021 | 16 Feb 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ANNUAL FINANCIAL REPORT | 16 Feb 2021 | 16 Feb 2021 | 001-11960 |
| 20-F | Open Document | Data | Open Filing | 20-F | 16 Feb 2021 | 31 Dec 2020 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 12 Feb 2021 | ||
| 425 | Open Document | Open Filing | 425 | 11 Feb 2021 | ||
| 425 | Open Document | Open Filing | 425 | 11 Feb 2021 | ||
| 425 | Open Document | Open Filing | 425 | 11 Feb 2021 | ||
| 425 | Open Document | Open Filing | 425 | 11 Feb 2021 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA NON-EXECUTIVE BOARD CHANGES | 11 Feb 2021 | 11 Feb 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN: FULL-YEAR 2020 RESULTS | 11 Feb 2021 | 11 Feb 2021 | 001-11960 |
| SC 13G | Open Document | Open Filing | SC 13G | 10 Feb 2021 | ||
| SC 13G/A | Open Document | Open Filing | SC 13G/A | 10 Feb 2021 | ||
| 6-K | Open Document | Open Filing | DIVESTMENT OF CRESTOR IN EUROPE COMPLETED | 10 Feb 2021 | 10 Feb 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI | 05 Feb 2021 | 05 Feb 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA APPROVED IN CHINA FOR HEART FAILURE | 04 Feb 2021 | 04 Feb 2021 | 001-11960 |
| SC 13G/A | Open Document | Open Filing | SEC SCHEDULE 13G | 03 Feb 2021 | 005-55247 | |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Feb 2021 | 01 Feb 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING | 01 Feb 2021 | 01 Feb 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | COVID-19 VACCINE AUTHORISED FOR USE BY THE EU | 01 Feb 2021 | 01 Feb 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU | 29 Jan 2021 | 29 Jan 2021 | 001-11960 |
| SC 13G/A | Open Document | Open Filing | 29 Jan 2021 | 005-55247 | ||
| 6-K | Open Document | Open Filing | BLOCK LISTING APPLICATION | 26 Jan 2021 | 26 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA | 26 Jan 2021 | 26 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE APPROVED IN JAPAN FOR CLL | 25 Jan 2021 | 25 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB | 25 Jan 2021 | 25 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN THE EU FOR BREAST CANCER | 20 Jan 2021 | 20 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU APPROVED IN THE US FOR GASTRIC CANCER | 19 Jan 2021 | 19 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO | 15 Jan 2021 | 15 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR | 06 Jan 2021 | 06 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 04 Jan 2021 | 04 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED | 04 Jan 2021 | 04 Jan 2021 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK | 30 Dec 2020 | 30 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P | 29 Dec 2020 | 29 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST | 21 Dec 2020 | 21 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS | 21 Dec 2020 | 21 Dec 2020 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 18 Dec 2020 | ||
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 17 Dec 2020 | 17 Dec 2020 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 17 Dec 2020 | ||
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 16 Dec 2020 | 16 Dec 2020 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 15 Dec 2020 | ||
| 6-K | Open Document | Open Filing | IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION | 15 Dec 2020 | 15 Dec 2020 | 001-11960 |
| 425 | Open Document | Open Filing | 425 | 14 Dec 2020 | ||
| 425 | Open Document | Open Filing | 425 | 14 Dec 2020 | ||
| 425 | Open Document | Open Filing | 425 | 14 Dec 2020 | ||
| 425 | Open Document | Open Filing | 425 | 14 Dec 2020 | ||
| 6-K | Open Document | Open Filing | TRASTUZUMAB DERUXTECAN POSITIVE CHMP | 14 Dec 2020 | 14 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD | 14 Dec 2020 | 14 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC | 14 Dec 2020 | 14 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 01 Dec 2020 | 01 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Dec 2020 | 01 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE | 01 Dec 2020 | 01 Dec 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE | 30 Nov 2020 | 30 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 | 23 Nov 2020 | 23 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI NEW DOSING APPROVED IN THE US | 20 Nov 2020 | 20 Nov 2020 | 001-11960 |
| 25-NSE | Open Document | Open Filing | 13 Nov 2020 | 001-11960 | ||
| 6-K | Open Document | Open Filing | TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT | 10 Nov 2020 | 10 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE APPROVED IN THE EU FOR CLL | 09 Nov 2020 | 09 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | BRILINTA APPROVED IN THE US IN STROKE | 06 Nov 2020 | 06 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN: YEAR-TO-DATE AND Q3 2020 RESULTS | 05 Nov 2020 | 05 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA APPROVED IN THE EU FOR HEART FAILURE | 05 Nov 2020 | 05 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F | 05 Nov 2020 | 05 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT | 05 Nov 2020 | 05 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Nov 2020 | 02 Nov 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES | 30 Oct 2020 | 30 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTORATE CHANGE | 29 Oct 2020 | 29 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET | 28 Oct 2020 | 28 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA | 28 Oct 2020 | 28 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW | 20 Oct 2020 | 20 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA HF RECEIVES POSITIVE CHMP OPINION | 19 Oct 2020 | 19 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION | 19 Oct 2020 | 19 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING | 13 Oct 2020 | 13 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE | 02 Oct 2020 | 02 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Oct 2020 | 01 Oct 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTORATE CHANGE | 25 Sep 2020 | 25 Sep 2020 | 001-11960 |
| CERT | Open Document | Open Filing | 24 Sep 2020 | 001-11960 | ||
| 8-A12B | Open Document | Open Filing | 8-A12B | 24 Sep 2020 | 001-11960 | |
| 25 | Open Document | Open Filing | 25 | 24 Sep 2020 | 001-11960 | |
| 6-K | Open Document | Open Filing | LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC | 21 Sep 2020 | 21 Sep 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT | 21 Sep 2020 | 21 Sep 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUV | 21 Sep 2020 | 21 Sep 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQ | 10 Sep 2020 | 10 Sep 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE I | 10 Sep 2020 | 10 Sep 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Sep 2020 | 01 Sep 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCER | 01 Sep 2020 | 01 Sep 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATH | 01 Sep 2020 | 01 Sep 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PRE | 25 Aug 2020 | 25 Aug 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG C | 21 Aug 2020 | 21 Aug 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE | 18 Aug 2020 | 18 Aug 2020 | 001-11960 |
| CERT | Open Document | Open Filing | NYSE CERTIFICATION | 12 Aug 2020 | 001-11960 | |
| 8-A12B | Open Document | Open Filing | FORM 8-A12B | 06 Aug 2020 | 001-11960 | |
| 6-K | Open Document | Open Filing | FORM 6-K | 06 Aug 2020 | 06 Aug 2020 | 001-11960 |
| 424B2 | Open Document | Open Filing | FORM 424B2 | 05 Aug 2020 | 333-234586 | |
| 6-K | Open Document | Open Filing | ASTRAZENECA PRICES A $3BN BOND ISSUE | 04 Aug 2020 | 04 Aug 2020 | 001-11960 |
| FWP | Open Document | Open Filing | FORM FWP | 04 Aug 2020 | 333-234586 | |
| S-8 | Open Document | Open Filing | S-8 | 03 Aug 2020 | 333-240298 | |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Aug 2020 | 03 Aug 2020 | 001-11960 |
| FWP | Open Document | Open Filing | FORM FWP | 03 Aug 2020 | 333-234586 | |
| 424B2 | Open Document | Open Filing | FORM 424B2 | 03 Aug 2020 | 333-234586 | |
| 6-K/A | Open Document | Data | Open Filing | 6-K/A | 31 Jul 2020 | 30 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN: H1 2020 RESULTS | 30 Jul 2020 | 30 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO US BTD FOR EGFRM ADJUVANT LUNG CANCER | 30 Jul 2020 | 30 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | BOARD COMMITTEE CHANGES | 29 Jul 2020 | 29 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA DAPA-CKD TRIAL MET ALL ENDPOINTS | 28 Jul 2020 | 28 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI RECOMMENDED FOR EU APPROVAL IN SCLC | 27 Jul 2020 | 27 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE RECEIVES POSITIVE CHMP OPINION FOR CLL | 27 Jul 2020 | 27 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGY | 27 Jul 2020 | 27 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPD | 24 Jul 2020 | 24 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 22 Jul 2020 | 22 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 22 Jul 2020 | 22 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 21 Jul 2020 | 21 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 21 Jul 2020 | 21 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN P | 20 Jul 2020 | 20 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR DECLARATION | 16 Jul 2020 | 16 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE | 09 Jul 2020 | 09 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER | 08 Jul 2020 | 08 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jul 2020 | 01 Jul 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 30 Jun 2020 | 30 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE | 30 Jun 2020 | 30 Jun 2020 | 001-11960 |
| 11-K | Open Document | Open Filing | 26 Jun 2020 | 31 Dec 2019 | 001-11960 | |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 17 Jun 2020 | 17 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 17 Jun 2020 | 17 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'S | 15 Jun 2020 | 15 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUS | 11 Jun 2020 | 11 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jun 2020 | 01 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 01 Jun 2020 | 01 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC | 01 Jun 2020 | 01 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE | 01 Jun 2020 | 01 Jun 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2- | 29 May 2020 | 29 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE | 29 May 2020 | 29 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM | 29 May 2020 | 29 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 26 May 2020 | 26 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER | 22 May 2020 | 22 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST | 21 May 2020 | 21 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT | 20 May 2020 | 20 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER | 18 May 2020 | 18 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD | 18 May 2020 | 18 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET | 11 May 2020 | 11 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM | 11 May 2020 | 11 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F | 11 May 2020 | 11 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H | 06 May 2020 | 06 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 May 2020 | 01 May 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | RESULT OF AGM | 29 Apr 2020 | 29 Apr 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN: FIRST-QUARTER 2020 RESULTS | 29 Apr 2020 | 29 Apr 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B | 24 Apr 2020 | 24 Apr 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING | 17 Apr 2020 | 17 Apr 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT | 14 Apr 2020 | 14 Apr 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC | 14 Apr 2020 | 14 Apr 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED | 02 Apr 2020 | 02 Apr 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Apr 2020 | 01 Apr 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 31 Mar 2020 | 31 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA | 30 Mar 2020 | 30 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER | 30 Mar 2020 | 30 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 26 Mar 2020 | 26 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA | 26 Mar 2020 | 26 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 20 Mar 2020 | 20 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA | 19 Mar 2020 | 19 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE | 17 Mar 2020 | 17 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | 6-K | 12 Mar 2020 | 12 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | NOTICE OF AGM | 12 Mar 2020 | 12 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS | 12 Mar 2020 | 12 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 10 Mar 2020 | 10 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S | 06 Mar 2020 | 06 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FILING OF FORM 20-F WITH SEC | 04 Mar 2020 | 04 Mar 2020 | 001-11960 |
| IRANNOTICE | Open Document | Open Filing | IRANNOTICE | 03 Mar 2020 | 001-11960 | |
| 20-F | Open Document | Data | Open Filing | 20-F | 03 Mar 2020 | 31 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ANNUAL FINANCIAL REPORT | 03 Mar 2020 | 03 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Mar 2020 | 02 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY | 02 Mar 2020 | 02 Mar 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 27 Feb 2020 | 27 Feb 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK | 25 Feb 2020 | 25 Feb 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 19 Feb 2020 | 19 Feb 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN: FULL-YEAR AND Q4 2019 RESULTS | 14 Feb 2020 | 14 Feb 2020 | 001-11960 |
| 4 | Open Document | Open Filing | 4 | 07 Feb 2020 | 19 Dec 2019 | 001-35112 |
| 3 | Open Document | Open Filing | 3 | 07 Feb 2020 | 19 Dec 2019 | 001-35112 |
| SC 13D | Open Document | Open Filing | SC 13D | 07 Feb 2020 | ||
| EFFECT | Open Document | Open Filing | 06 Feb 2020 | 333-236014 | ||
| SC 13G/A | Open Document | Open Filing | 05 Feb 2020 | 005-55247 | ||
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Feb 2020 | 03 Feb 2020 | 001-11960 |
| SC 13G | Open Document | Open Filing | SC 13G | 30 Jan 2020 | ||
| SC 13G/A | Open Document | Open Filing | SEC SCHEDULE 13G | 27 Jan 2020 | 005-55247 | |
| 6-K | Open Document | Open Filing | PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP | 27 Jan 2020 | 27 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN | 27 Jan 2020 | 27 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE | 27 Jan 2020 | 27 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES | 27 Jan 2020 | 27 Jan 2020 | 001-11960 |
| F-6 | Open Document | Open Filing | FORM F-6 | 22 Jan 2020 | 333-236014 | |
| 6-K | Open Document | Open Filing | LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED | 21 Jan 2020 | 20 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN | 21 Jan 2020 | 20 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA | 13 Jan 2020 | 13 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA | 13 Jan 2020 | 13 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA | 06 Jan 2020 | 06 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED | 06 Jan 2020 | 06 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Jan 2020 | 02 Jan 2020 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- | 30 Dec 2019 | 30 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP | 23 Dec 2019 | 23 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB | 23 Dec 2019 | 23 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO | 20 Dec 2019 | 20 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER | 17 Dec 2019 | 17 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA | 16 Dec 2019 | 16 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL | 12 Dec 2019 | 12 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE | 11 Dec 2019 | 11 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV | 05 Dec 2019 | 05 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA | 03 Dec 2019 | 03 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 02 Dec 2019 | 02 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Dec 2019 | 02 Dec 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE | 29 Nov 2019 | 29 Nov 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM | 21 Nov 2019 | 21 Nov 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2D | 15 Nov 2019 | 15 Nov 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIB | 14 Nov 2019 | 14 Nov 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIE | 12 Nov 2019 | 12 Nov 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO I | 12 Nov 2019 | 12 Nov 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASE | 08 Nov 2019 | 08 Nov 2019 | 001-11960 |
| F-3ASR | Open Document | Open Filing | FORM F-3ASR | 08 Nov 2019 | 333-234586 | |
| 6-K | Open Document | Open Filing | CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LIN | 06 Nov 2019 | 06 Nov 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Nov 2019 | 01 Nov 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIA | 30 Oct 2019 | 30 Oct 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYED | 28 Oct 2019 | 28 Oct 2019 | 001-11960 |
| SC 13D | Open Document | Open Filing | SC 13D | 25 Oct 2019 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTS | 24 Oct 2019 | 24 Oct 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU | 21 Oct 2019 | 21 Oct 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT | 17 Oct 2019 | 17 Oct 2019 | 001-11960 |
| 4 | Open Document | Open Filing | FORM 4 SUBMISSION | 09 Oct 2019 | 07 Oct 2019 | 001-39067 |
| 3/A | Open Document | Open Filing | FORM 3/A SUBMISSION | 09 Oct 2019 | 02 Oct 2019 | 001-39067 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 04 Oct 2019 | 04 Oct 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 04 Oct 2019 | 04 Oct 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATION | 04 Oct 2019 | 04 Oct 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR DECLARATION | 03 Oct 2019 | 03 Oct 2019 | 001-11960 |
| 3 | Open Document | Open Filing | FORM 3 SUBMISSION | 02 Oct 2019 | 02 Oct 2019 | 001-39067 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Oct 2019 | 01 Oct 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR | 01 Oct 2019 | 01 Oct 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD | 01 Oct 2019 | 01 Oct 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN | 30 Sep 2019 | 30 Sep 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS | 30 Sep 2019 | 30 Sep 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN | 30 Sep 2019 | 30 Sep 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP | 23 Sep 2019 | 23 Sep 2019 | 001-11960 |
| 25-NSE | Open Document | Open Filing | 18 Sep 2019 | 001-11960 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA | 18 Sep 2019 | 18 Sep 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP | 09 Sep 2019 | 09 Sep 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE | 04 Sep 2019 | 04 Sep 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Sep 2019 | 03 Sep 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC | 03 Sep 2019 | 03 Sep 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART | 03 Sep 2019 | 03 Sep 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS | 29 Aug 2019 | 29 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS | 28 Aug 2019 | 28 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS | 28 Aug 2019 | 28 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND | 22 Aug 2019 | 22 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW | 22 Aug 2019 | 22 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON THE PHASE III NEPTUNE TRIAL | 21 Aug 2019 | 21 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE III | 20 Aug 2019 | 20 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTORATE CHANGE | 19 Aug 2019 | 19 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATION | 14 Aug 2019 | 14 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINT | 14 Aug 2019 | 14 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL | 09 Aug 2019 | 09 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA PHASE III PROFOUND TRIAL IN HRR* | 07 Aug 2019 | 07 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETES | 05 Aug 2019 | 05 Aug 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Aug 2019 | 01 Aug 2019 | 001-11960 |
| 6-K | Open Document | Data | Open Filing | 6-K | 25 Jul 2019 | 30 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON US REGULATORY DECISION FOR FARXIGA | 15 Jul 2019 | 15 Jul 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER | 12 Jul 2019 | 12 Jul 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF | 01 Jul 2019 | 01 Jul 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Jul 2019 | 01 Jul 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR | 01 Jul 2019 | 01 Jul 2019 | 001-11960 |
| 11-K | Open Document | Open Filing | 27 Jun 2019 | 31 Dec 2018 | 001-11960 | |
| 6-K | Open Document | Open Filing | IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIM | 27 Jun 2019 | 27 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI | 19 Jun 2019 | 19 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA | 19 Jun 2019 | 19 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFA | 19 Jun 2019 | 19 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN THE EU FOR 1ST-LINE | 18 Jun 2019 | 18 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENT | 17 Jun 2019 | 17 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | PUBLICATION OF A PROSPECTUS | 12 Jun 2019 | 12 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY | 06 Jun 2019 | 06 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 03 Jun 2019 | 03 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Jun 2019 | 03 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM | 03 Jun 2019 | 03 Jun 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III | 10 May 2019 | 10 May 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 08 May 2019 | 08 May 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR DECLARATION | 08 May 2019 | 08 May 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLY | 08 May 2019 | 08 May 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINT | 07 May 2019 | 07 May 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETES | 03 May 2019 | 03 May 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 May 2019 | 01 May 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 01 May 2019 | 01 May 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1ST | 29 Apr 2019 | 29 Apr 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | RESULT OF AGM | 26 Apr 2019 | 26 Apr 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN: Q1 2019 RESULTS | 26 Apr 2019 | 26 Apr 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVE | 10 Apr 2019 | 10 Apr 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 04 Apr 2019 | 04 Apr 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 03 Apr 2019 | 03 Apr 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Apr 2019 | 02 Apr 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Apr 2019 | 01 Apr 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION | 01 Apr 2019 | 01 Apr 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | RESULTS OF PLACING | 29 Mar 2019 | 29 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVEL | 29 Mar 2019 | 29 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETES | 27 Mar 2019 | 27 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA APPROVED IN EUROPE FOR TYPE-1 DIABETES | 25 Mar 2019 | 25 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | US FDA GRANTS SARACATINIB ODD FOR IPF | 18 Mar 2019 | 18 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | NOTICE OF AGM | 14 Mar 2019 | 14 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | 6-K | 14 Mar 2019 | 14 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 12 Mar 2019 | 12 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FILING OF FORM 20-F WITH SEC | 06 Mar 2019 | 06 Mar 2019 | 001-11960 |
| IRANNOTICE | Open Document | Open Filing | IRANNOTICE | 05 Mar 2019 | 001-11960 | |
| 20-F | Open Document | Data | Open Filing | 20-F | 05 Mar 2019 | 31 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | ANNUAL FINANCIAL REPORT | 05 Mar 2019 | 05 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Mar 2019 | 01 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA RECEIVES POSITIVE EU CHMP OPINION | 01 Mar 2019 | 01 Mar 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION | 26 Feb 2019 | 26 Feb 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT | 25 Feb 2019 | 25 Feb 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA FULL-YEAR AND Q4 2018 RESULTS | 14 Feb 2019 | 14 Feb 2019 | 001-11960 |
| SC 13G/A | Open Document | Open Filing | SEC SCHEDULE 13G | 12 Feb 2019 | 005-55247 | |
| 6-K | Open Document | Open Filing | US FDA GRANTS FASENRA ORPHAN DRUG DESIGNATION | 06 Feb 2019 | 06 Feb 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION | 05 Feb 2019 | 05 Feb 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | EMA GRANTS PRIME ELIGIBILITY FOR MEDI8897 | 05 Feb 2019 | 05 Feb 2019 | 001-11960 |
| SC 13G/A | Open Document | Open Filing | 04 Feb 2019 | 005-55247 | ||
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Feb 2019 | 01 Feb 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | FORXIGA RECEIVES POSITIVE EU CHMP OPINION | 01 Feb 2019 | 01 Feb 2019 | 001-11960 |
| SC 13G | Open Document | Open Filing | SC 13G | 30 Jan 2019 | ||
| 6-K | Open Document | Open Filing | COMPLETION OF DIVESTMENT OF US SYNAGIS RIGHTS | 25 Jan 2019 | 25 Jan 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES | 07 Jan 2019 | 07 Jan 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Jan 2019 | 02 Jan 2019 | 001-11960 |
| 6-K | Open Document | Open Filing | BEVESPI AEROSPHERE APPROVED IN THE EU FOR COPD | 20 Dec 2018 | 20 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL | 20 Dec 2018 | 20 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS | 20 Dec 2018 | 20 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPY | 19 Dec 2018 | 19 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISE | 18 Dec 2018 | 18 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTORATE CHANGE | 14 Dec 2018 | 14 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | UPDATE ON THE PHASE III EAGLE TRIAL OF IMFINZI | 07 Dec 2018 | 07 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | DIVESTMENT OF RIGHTS TO COVIS COMPLETED | 06 Dec 2018 | 06 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTOR/PDMR SHAREHOLDING | 04 Dec 2018 | 04 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | BLOCK LISTING INTERIM REVIEW | 03 Dec 2018 | 03 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 03 Dec 2018 | 03 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | GRUNENTHAL AGREEMENT FOR NEXIUM VIMOVO COMPLETED | 03 Dec 2018 | 03 Dec 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | US FDA GRANTS FASENRA ODD FOR EGPA | 26 Nov 2018 | 26 Nov 2018 | 001-11960 |
| 25-NSE | Open Document | Open Filing | 16 Nov 2018 | 001-11960 | ||
| 25-NSE | Open Document | Open Filing | 16 Nov 2018 | 001-11960 | ||
| 6-K | Open Document | Open Filing | ASTRAZENECA PROVIDES UPDATE ON PHASE III MYSTIC | 16 Nov 2018 | 16 Nov 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI | 13 Nov 2018 | 13 Nov 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | US FDA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA | 13 Nov 2018 | 13 Nov 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA SIGNIFICANTLY REDUCED HOSPITALISATION FOR | 13 Nov 2018 | 13 Nov 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | AZN: YEAR-TO-DATE AND Q3 2018 RESULTS | 08 Nov 2018 | 08 Nov 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | DIVESTMENT OF RIGHTS TO COVIS PHARMA | 06 Nov 2018 | 06 Nov 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Nov 2018 | 01 Nov 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | ADDITIONAL FINANCIAL INFORMATION-GRUNENTHAL DEAL | 31 Oct 2018 | 31 Oct 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | GRUNENTHAL AGREEMENT FOR RIGHTS TO NEXIUM VIMOVO | 30 Oct 2018 | 30 Oct 2018 | 001-11960 |
| SC 13D | Open Document | Open Filing | SC 13D | 29 Oct 2018 | ||
| 4 | Open Document | Open Filing | FORM 4 SUBMISSION | 24 Oct 2018 | 22 Oct 2018 | 001-38697 |
| 6-K | Open Document | Open Filing | ASTRAZENECA EXTENDS INNATE PHARMA COLLABORATION | 23 Oct 2018 | 23 Oct 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA SHOWS 70% REDUCTION IN PFS OVARIAN CANCER | 22 Oct 2018 | 22 Oct 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | CHMP POSITIVE OPINION BEVESPI AEROSPHERE | 19 Oct 2018 | 19 Oct 2018 | 001-11960 |
| 3 | Open Document | Open Filing | FORM 3 SUBMISSION | 17 Oct 2018 | 17 Oct 2018 | 001-38697 |
| 6-K | Open Document | Open Filing | FDA ORPHAN DRUG FOR LYNPARZA IN PANCREATIC CANCER | 16 Oct 2018 | 16 Oct 2018 | 001-11960 |
| SC 13D/A | Open Document | Open Filing | SC 13D/A | 12 Oct 2018 | ||
| SC 13D | Open Document | Open Filing | SC 13D | 05 Oct 2018 | ||
| 4 | Open Document | Open Filing | FORM 4 SUBMISSION | 02 Oct 2018 | 28 Sep 2018 | 001-38670 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Oct 2018 | 01 Oct 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | ATACAND AGREEMENT WITH CHEPLAPHARM COMPLETED | 01 Oct 2018 | 01 Oct 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NED | 28 Sep 2018 | 28 Sep 2018 | 001-11960 |
| 3 | Open Document | Open Filing | FORM 3 SUBMISSION | 25 Sep 2018 | 25 Sep 2018 | 001-38670 |
| 6-K | Open Document | Open Filing | OVERALL SURVIVAL DATA FOR IMFINZI: STAGE III NSCLC | 25 Sep 2018 | 25 Sep 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | EMA APPROVES AZ'S IMFINZI FOR STAGE III NSCLC | 24 Sep 2018 | 24 Sep 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | FARXIGA GETS POSITIVE RESULT IN DECLARE-TIMI 58 | 24 Sep 2018 | 24 Sep 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | FDA APPROVES AZS LUMOXITI IN HAIRY CELL LEUKAEMIA | 14 Sep 2018 | 14 Sep 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | TEZEPELUMAB FDA BREAKTHROUGH THERAPY DESIGNATION | 07 Sep 2018 | 07 Sep 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | DIRECTORATE CHANGE | 06 Sep 2018 | 06 Sep 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 04 Sep 2018 | 04 Sep 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | ASTRAZENECA UPDATE ON ANIFROLUMAB IN SLE | 31 Aug 2018 | 31 Aug 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | EC APPROVES BYDUREON BCISE DEVICE FOR T2 DIABETES | 30 Aug 2018 | 30 Aug 2018 | 001-11960 |
| CERT | Open Document | Open Filing | NYSE CERTIFICATION - ASTRAZENECA PLC | 23 Aug 2018 | 001-11960 | |
| 6-K | Open Document | Open Filing | ASTRAZENECA PIIIB TRIAL UPDATE FOR BEVESPI IN COPDASTRAZENECA PIIIB TRIAL UPDATE | 23 Aug 2018 | 23 Aug 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | AZ'S TAGRISSO APPROVED IN JAPAN FOR 1ST-LINE NSCLC | 21 Aug 2018 | 21 Aug 2018 | 001-11960 |
| 8-A12B | Open Document | Open Filing | FORM 8-A12B | 17 Aug 2018 | 001-11960 | |
| 6-K | Open Document | Open Filing | FORM 6-K | 17 Aug 2018 | 17 Aug 2018 | 001-11960 |
| 424B2 | Open Document | Open Filing | FORM 424B2 | 16 Aug 2018 | 333-214756 | |
| 6-K | Open Document | Open Filing | ASTRAZENECA PRICES A $3BN BOND ISSUE | 15 Aug 2018 | 15 Aug 2018 | 001-11960 |
| FWP | Open Document | Open Filing | FORM FWP | 15 Aug 2018 | 333-214756 | |
| S-8 | Open Document | Open Filing | S-8 | 14 Aug 2018 | 333-226830 | |
| FWP | Open Document | Open Filing | FORM FWP | 14 Aug 2018 | 333-214756 | |
| 424B2 | Open Document | Open Filing | FORM 424B2 | 14 Aug 2018 | 333-214756 | |
| 6-K | Open Document | Open Filing | 6-K | 10 Aug 2018 | 10 Aug 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | EMA GRANTS OD FOR SELUMETINIB IN NF1 | 03 Aug 2018 | 03 Aug 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 01 Aug 2018 | 01 Aug 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | CHMP RECOMMENDS IMFINZI FOR STAGE III NSCLC | 27 Jul 2018 | 27 Jul 2018 | 001-11960 |
| 6-K | Open Document | Data | Open Filing | 6-K | 26 Jul 2018 | 26 Jul 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | ATACAND TO BE DIVESTED TO CHEPLAPHARM IN EUROPE | 24 Jul 2018 | 24 Jul 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | HOLDING(S) IN COMPANY | 18 Jul 2018 | 18 Jul 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | TOTAL VOTING RIGHTS | 02 Jul 2018 | 02 Jul 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | LYNPARZA APPROVED IN JAPAN FOR BRCAM BREAST CANCER | 02 Jul 2018 | 02 Jul 2018 | 001-11960 |
| 6-K | Open Document | Open Filing | IMFINZI APPROVED IN JAPAN FOR STAGE III NSCLC | 02 Jul 2018 | 02 Jul 2018 | 001-11960 |